DDInter1939 DDInter1676
Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-generation drugs (vinorelbine, gemcitabine, taxanes) in platinum combination improved survival of patients with advanced NSCLC, with very similar results from the various drugs. Treatment toxicities are considerable in the combination treatment setting. A study was done on the clearance rate of vinorelbine on individuals with various single polymorphonuclear mutations. It was found that there was 4.3-fold variation in vinorelbine clearance across the cohort, suggesting a strong influence of genetics on the clearance of this drug.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Vinorelbine {u} (Compound) resembles {v} (Compound) Vincristine
Vinorelbine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinblastine
Vinorelbine {u} (Compound) treats {v} (Disease) hematologic cancer
Vinorelbine {u} (Compound) binds {v} (Gene) TUBB4B
Vinorelbine {u} (Compound) upregulates {v} (Gene) LAMC2
Vinorelbine {u} (Compound) is included by {v} (Pharmacologic Class) Vinca Alkaloids
Vinorelbine {u} (Compound) downregulates {v} (Gene) IARS2
Vinorelbine {u} (Compound) causes {v} (Side Effect) Angina pectoris
Vinorelbine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Vinorelbine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Moxifloxacin
Vinorelbine (Compound) resembles Vincristine (Compound)
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine
Vinorelbine (Compound) treats hematologic cancer (Disease)
Vinorelbine (Compound) binds TUBB4B (Gene)
Vinorelbine (Compound) upregulates LAMC2 (Gene)
Vinorelbine (Compound) is included by Vinca Alkaloids (Pharmacologic Class)
Vinorelbine (Compound) downregulates IARS2 (Gene)
Vinorelbine (Compound) causes Angina pectoris (Side Effect)
Vinorelbine may cause a minor interaction that can limit clinical effects when taken with Modafinil
Vinorelbine may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin